Connective Therapeutics Names Scott Harkonen Senior VP, Product Development and Operations.PALO ALTO, Calif.--(BUSINESS WIRE)--Aug. 14, 1995--Connective Therapeutics, Inc. today announced the appointment of W. Scott Harkonen, M.D., 43, as senior vice president of product development and operations, effective September 1. Dr. Harkonen has over 12 years of experience in the biotechnology industry, and is currently vice president of medical and regulatory affairs at Univax Biologics, Inc. Prior to joining Univax in 1991, he held various product development positions at Scios Nova and Xoma Corporation. While at Univax, he was instrumental in building the clinical and regulatory function and gaining the approval of WinRho SD, Rh, (D) Immune Globulin Immune globulin Serum containing antibodies against a specific infection. Mentioned in: Maternal to Fetal Infections Intravenous (Human). WinRho SD was granted a marketing license in March of this year for the treatment of immune thrombocytopenic purpura immune thrombocytopenic purpura n. See idiopathic thrombocytopenic purpura. immune thrombocytopenic purpura Idiopathic thrombocytopenic purpura, see there and the suppression of Rh isoimmunization. Dr. Harkonen received his B.A. and M.D. degrees from the University of Minnesota (body, education) University of Minnesota - The home of Gopher. http://umn.edu/. Address: Minneapolis, Minnesota, USA. , and received an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from the Haas School of Business, University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal . He trained in internal medicine at the University of Minnesota and in allergy, clinical immunology and clinical pharmacology at the University of California, San Francisco . He previously held academic and research appointments at UCSF UCSF University of California at San Francisco and Stanford University. "We are delighted to have Dr. Harkonen join Connective," said Thomas G. Wiggans, president and chief executive officer of Connective. "His experience in product development, registration and overall biotech company development issues will make him a great addition to the management team. Scott's arrival will help us expand our clinical development programs for relaxin re·lax·in n. A female hormone secreted by the corpus luteum that helps soften the cervix and relax the pelvic ligaments in childbirth. relaxin, n and t-cell receptor peptides." Connective Therapeutics, founded in 1993, is a privately-held firm focused on the development of novel therapeutics for chronic connective tissue disorders. The company's therapeutic approaches are based on controlling cells that produce excessive or abnormal connective tissue, and on modulating the immune response directly associated with certain connective tissue diseases. The company's investors include Kleiner, Perkins, Caufield and Byers; Sierra Ventures; Domain Associates; Biotechnology Investments, Ltd.; the Sprout Group; GIMV, Sofinnova and Lease Management Services. Genentech, Inc. is a stockholder in the company. CONTACT: Connective Therapeutics Inc. Thomas G. Wiggans, 415/843-2800 or StratiPoint Group, Inc. Mike Jackman, 415/388-3216 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion